Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.

Arthritis Res Ther · 2019 · PMC6555014 · PMID 31174592

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

Although the comparative data currently available are limited and inconsistent, our findings are consistent with an overall trend toward a lower risk of hospitalized infections or SIs with abatacept compared with other bDMARDs [ 19 , 22 , 25 , 34 ].

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.